The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics draws attention to a key discussion by Targeted Oncology and Dr. Jeff Sharman on early safety findings for its ALPHA3 investigational therapy. The conversation also examines the potential application of cema-cel in community outpatient settings, especially for patients with MRD-positive large B-cell lymphoma (LBCL).
The discussion is part of ongoing efforts to advance allogeneic CAR-T therapies and make innovative treatments more accessible outside academic centers. Further data on safety and clinical outcomes are expected as trials progress. Details are being clarified.
Allogene Therapeutics has recently provided pipeline and corporate strategy updates at the TD Cowen Oncology Innovation Summit webcast. The company also presented strategic developments at the Jefferies Global Healthcare Conference in New York. These events offer further context as Allogene advances new therapy candidates through clinical trials.